The Novel Compound Sul-121 Preserves Endothelial Function and Inhibits Progression of Kidney Damage in Type 2 Diabetes Mellitus in Mice by Lambooy, S P H et al.
  
 University of Groningen
The Novel Compound Sul-121 Preserves Endothelial Function and Inhibits Progression of
Kidney Damage in Type 2 Diabetes Mellitus in Mice
Lambooy, S P H; Bidadkosh, A; Nakladal, D; van Buiten, A; Girgis, R A T; van der Graaf, A C;





IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2017
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Lambooy, S. P. H., Bidadkosh, A., Nakladal, D., van Buiten, A., Girgis, R. A. T., van der Graaf, A. C., ...
Deelman, L. E. (2017). The Novel Compound Sul-121 Preserves Endothelial Function and Inhibits
Progression of Kidney Damage in Type 2 Diabetes Mellitus in Mice. Scientific Reports, 7(1), [11165].
https://doi.org/10.1038/s41598-017-11582-6
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 12-11-2019
1SCiENTifiC REPoRTS | 7: 11165  | DOI:10.1038/s41598-017-11582-6
www.nature.com/scientificreports
The Novel Compound Sul-121 
Preserves Endothelial Function 
and Inhibits Progression of Kidney 
Damage in Type 2 Diabetes Mellitus 
in Mice
S. P. H. Lambooy1, A. Bidadkosh1, D. Nakladal1,2, A. van Buiten1, R. A. T. Girgis1, A. C. van 
der Graaf3, T. J. Wiedenmann4, R. A. Koster1, P. Vogelaar  3, H. Buikema1, R. H. Henning1 & 
L. E. Deelman1
Diabetic nephropathy is still a common complication of type 2 diabetes mellitus (T2DM) and 
improvement of endothelial dysfunction (ED) and inhibition of reactive oxygen species (ROS) are 
considered important targets for new therapies. Recently, we developed a new class of compounds 
(Sul compounds) which inhibit mitochondrial ROS production. Here, we tested the therapeutic effects 
of Sul-121 on ED and kidney damage in experimental T2DM. Diabetic db/db and lean mice were 
implanted with osmotic pumps delivering Sul-121 (2.2 mg/kg/day) or vehicle from age 10 to 18 weeks. 
Albuminuria, blood pressure, endothelial mediated relaxation, renal histology, plasma creatinine, 
and H2O2 levels were assessed. Sul-121 prevented progression of albuminuria and attenuated kidney 
damage in db/db, as evidenced by lower glomerular fibronectin expression (~50%), decreased focal 
glomerular sclerosis score (~40%) and normalization of glomerular size and kidney weight. Further, 
Sul-121 restored endothelium mediated vasorelaxation through increased production of Nitric Oxide 
production and normalized plasma H2O2 levels. Sul-121 treatment in lean mice demonstrated no 
observable major side-effects, indicating that Sul-121 is well tolerated. Our data show that Sul-121 
inhibits progression of diabetic kidney damage via a mechanism that involves restoration of endothelial 
function and attenuation of oxidative stress.
Type 2 diabetes (T2DM) is a growing public health problem and is associated with both micro- and macrovascu-
lar complications. Diabetic nephropathy (DN) is a frequent microvascular complication of T2DM and is currently 
the most common cause of End Stage Renal Disease (ESRD)1.
Endothelial dysfunction (ED), the impaired release of relaxing factors by the vascular endothelium, is known 
to be a key factor in the development of microvascular complications and end organ damage in patients with 
T2DM2. In the kidney, ED may not only contribute to impaired renal hemodynamics, but also causes increased 
protein leakage over the filtration barrier3, 4. The resulting albuminuria is now recognized as an early step in the 
development of diabetic nephropathy5.
The vascular endothelium releases several vasoactive substances, including nitric oxide (NO), prostaglandins 
and Endothelium-Derived Hyperpolarizing Factors (EDHF). In contrast to NO and the prostaglandins, EDHF 
has not been characterized as a single factor but rather is believed a combination of factors depending on the vas-
cular bed studied. Potassium6, epoxyeicosatrienoic acids (EETs)7, C-type natriuretic peptide (CNP)8, 9 hydrogen 
peroxide (H2O2)10, 11 and more recently hydrogen sulfide (H2S)12 have all been identified as EDHFs.
In diabetes, oxidative stress is known to interact with the vasoactive substances released by the endothelium. 
Firstly, superoxides can react with NO, limiting the bioavailability of this vasodilator. Secondly, the generated 
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peroxynitrite can react with tyrosine residues in caveolar proteins, resulting in nitric oxide synthase (NOS) 
uncoupling and impaired NO release13. As antioxidants have shown little clinical value in diabetic patients14, new 
approaches aiming to reduce ROS production in diabetes could provide additional treatment strategies for halting 
the progression of kidney disease in type 2 diabetes.
Recently, we developed modified 6-chromanols which represent a new class of pharmacological compounds 
(named Sul compounds) that preserve cell viability under conditions of hypothermia15. Interestingly, under these 
conditions, Sul-compounds preserve mitochondrial membrane potential through activation of mitochondrial 
membrane complexes I and IV. As a result, Sul compounds alleviate mitochondrial ROS production and preserve 
ATP production. In addition to the effects on mitochondria, Sul compounds have an antioxidant capacity due 
to the 6-chromanol group also found in alpha-tocopherol (Vitamin E) and Trolox. Although we reported these 
actions for the compound Sul-10915, identical results were obtained for Sul-121 (unpublished data). However, 
because of the better solubility of Sul-121 in the medium for the osmotic mini-pumps, Sul-121 was chosen over 
Sul-109 in the present study.
Given the effects of Sul compounds on mitochondrial ROS production, we hypothesized that Sul compounds 
may reduce ROS production and consequently improve ED in experimental diabetes. Here, we describe the 
effects of long term subcutaneous administration (8 weeks) of compound Sul-121 on the development of renal 
damage and endothelial dysfunction in the db/db model of type 2 diabetes.
Results
Animal characteristics. Animal characteristics are shown in Fig. 1 and Table 1. As expected, db/db mice 
had a higher body weight compared to lean mice (Fig. 1A). db/db mice gradually lost weight as of week 4. 
However, Sul-121 did not affect body weight at any time point. Non-fasting blood glucose levels were significantly 
increased in the db/db mice compared to lean mice (Fig. 1B). During the course of the experiment, non-fasting 
blood glucose levels in the db/db animals rose from 27.5 ± 2.5 and 27.2 ± 1.3 g (db/db vehicle and db/db Sul-121, 
respectively) to 35.8 ± 2.4 and 35.3 ± 1.1 mM, indicating a severe and progressive diabetic state. Treatment with 
Sul-121 did not affect blood glucose levels.
At termination, kidney and liver weights were measured (Table 1). In db/db vehicle, both left and right kid-
ney weights were significantly increased (261.7 ± 11.5 and 289.6 ± 7.8 mg, respectively) compared to lean vehi-
cle (227.2 ± 4.5 and 252.1 ± 6.0 mg, respectively). Sul-121 treatment normalized left and right kidney weights 
(233.1 ± 4.9 and 252.7 ± 7.3 mg, respectively). Liver weights were similarly increased in both db/db vehicle 
(2194 ± 92 mg) and db/db Sul-121 (2030 ± 63 mg) compared to lean vehicle (1356 ± 42 mg). Mean Arterial blood 
pressure was measured at week 6. Blood pressure was higher in db/db mice (85.7 ± 3.4 mmHg) compared to lean 
mice (74.1 ± 5.2 mmHg) and was not affected by Sul-121 treatment.
Plasma creatinine levels (Table 1) were similarly increased in both db/db vehicle (1.96 ± 0.11 μmol/l) and db/
db Sul-121 (2.16 ± 0.30 μmol/l) compared to lean vehicle (1.75 ± 0.17 μmol/l). In lean Sul-121 mice, plasma cre-
atinine levels were lower (1.24 ± 0.12 μmol/l) compared to lean vehicle.
Sul-121 plasma levels in db/db and lean mice. Plasma Sul-121 levels were not normally distributed and 
ranged from 12 to 111 µg/l (median 50 µg/l) in lean Sul-121 mice (Table 1). Sul-121 levels were significantly higher 
in db/db Sul-121 than in lean Sul-121 (p < 0.05, range 55–274 µg/l, median 82 µg/l). Sul-121 levels in lean vehicle 
and db/db vehicle mice were all below detection threshold (<10 ug/l).
The effects of Sul-121 on albuminuria. Urinary albumin excretion (AER) was measured throughout 
the duration of the experiment. Here, db/db vehicle mice showed an increase in AER from week 4 onwards 
reaching 1241 ± 204 µg/day by week 8. In db/db Sul-121, progression of AER was completely attenuated and AER 
remained stable at approximately 500 µg/day (Fig. 1C). AER in lean mice was measured at week 8 and amounted 
to 13.5 ± 1.9 and 12.5 ± 1.7 µg/day for lean vehicle and lean Sul-121 mice, respectively (Table 1).
Glomerular damage and renal histology. As Sul-121 had a profound effect on albuminuria, we assessed 
damage to the glomerulus using histological staining and Western blotting. Periodic acid–Schiff stainings of 
kidney sections are shown in Fig. 2, panels A-D. Subsequently, glomerular size (Fig. 2E) and glomerulosclerosis 
scores (Fig. 2F) were determined. Glomerular size was increased in db/db vehicle (124 ± 8% of control), which 
was normalized in db/db Sul-121 (98 ± 4% of control). Similarly, glomerulosclerosis score was increased in db/
db vehicle (166 ± 16% of control), which was significantly attenuated in db/db Sul-121 (140 ± 10% of control).
Glomerular damage was further assessed by immunohistochemistry. Expression of fibronectin, an extra cel-
lular matrix (ECM) protein, was found predominantly in glomeruli (Fig. 3A–D) and was most pronounced in db/
db vehicle (Fig. 3C). Fibronectin expression was further quantified by Western blotting in whole kidney homoge-
nates and found to be significantly upregulated in db/db vehicle (396 ± 19% of control) compared to their lean 
vehicle (100 ± 51%) (Fig. 3L). In db/db Sul-121, the increased fibronectin expression was significantly attenuated 
(194 ± 24% of control).
Podycyte loss was assessed by immunostaining for podocyte markers WT1 and synaptopodin (Fig. 3E–G and 
Supplementary Fig. 1). WT1 staining was confined to the nucleus and podocyte numbers were determined by 
automated counting of the average number of WT1 positive cells per glomerulus (Fig. 3M). Compared to lean 
vehicle (10.7 ± 0.2 cells per glomerulus), the number of WT1 positive podocytes was significantly reduced in 
both db/db vehicle (8.6 ± 0.5 cells) and db/db Sul-121 (8.3 ± 0.5). For synaptopodin, a trend towards lower syn-
aptopodin staining in db/db vehicle could be observed (Supplementary Fig. 1A,B). However, the decreased syn-
aptopodin staining in db/db vehicle did not reach statistical significance (p = 0.13). Expression of slit diaphragm 
proteins was assessed by Western blotting for Nephrin (Supplementary Fig. 1C). No significant differences could 
be observed between groups.
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Sirius red staining and polarized microscopy was used to visualize collagen I as marker of renal intersti-
tial damage (Fig. 3H–K). No differences in collagen I expression could be detected between groups (Fig. 3N). 
Additional markers for renal interstitial damage were assessed by real-time PCR (Fig. 4). Similar to the findings of 
the Sirius red staining, Collagen I mRNA expression was not different between groups (Fig. 4A). Smooth muscle 
actin expression (Fig. 4B) was increased in db/db vehicle (1.43 ± 0.31 arb. units) over lean vehicle (1.07 ± 0.09 arb. 
units), but not different in db/db Sul-121 (1.51 ± 0.16 arb. units). In addition, macrophage marker Macrosialin 
(CD68) and TNF-alpha expression was not different between groups (Fig. 4C,D). Interleukin Il-1B was upreg-
ulated in db/db vehicle (1.70 ± 0.48 arb. units) over lean vehicle (0.51 ± 0.10 arb. units) with a non-significant 
reduction in db/db Sul-121 (1.05 ± 0.31 arb. units) (Fig. 4E).
Effects of Sul-121 treatment on reactive oxygen species. Hydrogen peroxide, a stable metabolite of 
ROS, was taken as a reference for ROS levels in plasma (Fig. 5A). Plasma H2O2 was significantly increased in db/
db vehicle mice (0.46 ± 0.03 µM) compared to lean vehicle (0.33 ± 0.05 µM). Treatment of Sul-121 reduced H2O2 
Figure 1. Effects of Sul-121 treatment on metabolic parameters and albuminuria in db/db mice and in lean 
mice. (A) Body weight and (B) non-fasting plasma glucose levels throughout the duration of the experiment. 
(C) The progression in urinary albumin excretion rate was attenuated by Sul-121 treatment in db/db Sul-121 vs 
db/db vehicle, from week 6 onwards. *p < 0.05 db/db Sul-121 vs db/db vehicle, #p < 0.05 lean vs db/db.
www.nature.com/scientificreports/










body weight (g) 30.3 ± 0.6 30.2 ± 1.2 35.5 ± 1.5 34.8 ± 1.5
L kidney (mg) 227.2 ± 4.5 230.8 ± 7.8 261.7 ± 11.5* 233.1 ± 4.9#
R kidney (mg) 252.1 ± 6.0 264.1 ± 8.8 289.6 ± 7.8* 252.7 ± 7.3#
Liver (mg) 1356 ± 42 1388 ± 55 2194 ± 92* 2030 ± 63*
MABP (mmHg)(week 6) 74.1 ± 5.2 76.9 ± 6.5 85.7 ± 3.4* 87.5 ± 2.8*
24 h water consumption 
(weeks 2–8) 0.7 ± 5.2 0.8 ± 0.1 18.3 ± 1.2
* 15.9 ± 1.5*
24 h urine 
production(weeks 2–8) 4.1 ± 0.2 3.7 ± 0.4 18.6 ± 1.2
* 16.9 ± 1.6*
AER (μg/day) 13.5 ± 1.9 12.5 ± 1.7 1240.8 ± 203.9* 471.2 ± 132.2*#
plasma creat (μmol/l) 1.75 ± 0.17 1.24 ± 0.12* 1.96 ± 0.11* 2.16 ± 0.30*
plasma Sul-121 (μg/L)
(week 2, median (IQR)) Non-detectable 50 (30–54) Non-detectable 82 (66–235)†
Table 1. Animal characteristics. Animal characteristics at week 8 of treatment unless stated otherwise. 
*p < 0.05 versus lean control, #p < 0.05 versus db/db control, †p < 0.05 vs lean Sul-121.
Figure 2. Effects of Sul 121 treatment on glomerular histology. Representative pictures of PAS stainings are 
shown for lean vehicle (A), lean Sul-121 (B), db/db vehicle (C) and db/db Sul-121 (D). Inserts show details of 
glomerular staining. (E) Glomerular size was increased in db/db vehicle and normalized in db/db Sul-121. (F) 
Glomerulosclerosis scores were increased in db/db vehicle and significantly reduced in db/db Sul-121. *p < 0.05 
db/db vehicle vs lean vehicle, #p < 0.05 db/db Sul-121 vs db/db vehicle.
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Figure 3. Effect of Sul-121 treatment on renal fibronectin, WT1 and Collagen I expression. (A–D) Stainings 
of fibronectin (green), actin (red), and dapi (blue) are shown for lean vehicle (A), lean Sul-121 (B), db/db 
vehicle (C) and db/db Sul-121 (D). Increased fibronection staining is observed only in db/db vehicle (C). (E,F) 
Stainings of podocyte marker WT1 (red), fibronectin (green) and dapi (blue) shown for lean vehicle only. 
(E) Nuclear staining of WT1. (F) Overlay of fibronectin and dapi. (G) Overlay of WT1, fibronectin and dapi. 
(H–K) Representative pictures of polarization contrast microscopy of collagen I (indicated by white arrows) in 
lean vehicle (H), lean Sul-121 (I), db/db vehicle(J) and db/db Sul-121(K). (L) Renal fibronectin expression was 
additionally examined using Western blotting. Insert showing representative cropped blots for fibronectin and 
beta-actin as loading control. Renal fibronectin was significantly upregulated in db/db vehicle. Sul-121 reduced 
fibronectin expression in db/db Sul-121. (M) Quantification of the average number of WT1 positive nuclei 
per glomerulus. Decreased numbers of WT1 positive cells were present in db/db vehicle and db/db Sul-121. 
(N) Quantification of polarization contrast microscopy of collagen I. *p < 0.05 db/db vehicle vs lean vehicle, 
#p < 0.05 db/db Sul-121 vs db/db vehicle.
www.nature.com/scientificreports/
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levels in db/db mice (0.33 ± 0.06 µM) to lean vehicle levels. Urinary H2O2 levels (Fig. 5B) were similarly increased 
in both db/db vehicle and db/db Sul-121 (45.6 ± 6.8 and 54.5 ± 11.8 μmol/mmol, respectively) over controls 
(19.2 ±3.2 μmol/mmol). 
Furthermore, we examined the renal mRNA expression of superoxide dismutases SOD1, SOD2 and SOD3 
(Fig. 5C–E). SOD1 expression was decreased in db/db vehicle (0.38 ± 0.05 arb. units) compared to lean vehi-
cle (0.69 ± 0.12 arb. units) and was normalized in db/db Sul-121 (0.71 ± 0.09 arb. units). SOD2 expression was 
increased in db/db vehicle (1.22 ± 0.09 arb. units) compared to lean vehicle (0.88 ± 0.08 arb. units) and further 
increased in db/db Sul-121 (1.55 ± 0.10 arb. units). SOD3 expression demonstrated large variation with a trend 
towards increased SOD3 expression in db/db Sul121 (0.63 ± 0.17 arb. units) over db/db vehicle (0.37 ± 0.17 arb. 
units) although this did not reach statistical significance.
COX-2 expression (Fig. 5F) was increased in db/db vehicle (1.70 ± 0.49 arb. units) over lean vehicle 
(0.51 ± 0.10 arb. units). COX2 expression in db/db Sul-121 was intermediate (1.06 ± 0.33 arb. units) between lean 
vehicle and db/db vehicle and did not differ significantly from either group.
Glomerular protein carbonylation was determined in all groups (Fig. 5G and Supplementary Fig. 2). 
Surprisingly, lean Sul-121 showed increased protein carbonylation (118.0 ± 2.6 arb. units) over lean vehicle 
(106.8 ± 3.0 arb. units). In db/db vehicle, protein carbonylation was further increased (129.5 ± 3.2 arb. units), 
whereas this was not affected by Sul-121 treatment in db/db Sul-121 (126.0 ± 4.7 arb. units).
Figure 4. Effect of Sul-121 treatment on expression of markers of interstitial damage and inflammation. 
Expression of Collagen 1 (A), Smooth muscle actin (SMA) (B), Macrosialin (CD68) (C), TNF-alpha (D) and 
IL-1B (E) was assessed by real-time PCR. SMA expression was increased in db/db vehicle and db/db Sul-121(B). 
IL-1B was increased in db/db vehicle(E). *p < 0.05 db/db vehicle or db/db Sul-121 vs lean vehicle.
www.nature.com/scientificreports/
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The effects of Sul-121 on ROS production were further studied in an in-vitro model of diabetes (Fig. 5H). For 
this, cultured mouse renal mesangial cells were exposed to conditions simulating type 2 diabetes (high glucose 
and insulin). Exposure to high glucose and insulin increased the fluorescence of the ROS probe H2DCFDA by 
approximately 70% (Fig. 5H). Interestingly, Sul-121 pre-treatment did not affect basal levels of intracellular ROS, 
but substantially inhibited the increase in intracellular ROS provoked by glucose and insulin (p < 0.05).
To assess the effects of Sul-121 on renal mitochondrial ROS production, mitochondria were isolated from 
kidneys from an additional group of lean and db/db mice. Mitochondria obtained from db/db mice showed 
increased ROS production (3956 ± 241 arb. units) compared to lean mice (2832 ± 315 arb. units)(Fig. 5I). Acute 
treatment with Sul-121 lowered mitochondrial ROS production to similar levels in both lean control (1849 ± 206 
arb. units) and db/db (2302 ± 193 arb. units).
Vascular function in diabetes and the effect of Sul-121. As ROS and diabetes have profound effects 
on endothelial function, we next established the effects of Sul-121 treatment on endothelial function of the mouse 
aorta. For this, mouse aortic rings were preconstricted with phenylephrine (PE) and subsequently relaxed with 
stepwise incremental concentrations of acetylcholine (ACh). Concentration effect curves were constructed 
(Fig. 6A), demonstrating an impaired relaxation to ACh in db/db vehicle compared to lean vehicle (max. relaxa-
tion 39.2 ± 6.5% and 9.2 ± 1.6% for db/db vehicle and lean vehicle, respectively). In db/db Sul-121 mice, vasore-
laxation was completely restored to lean vehicle levels (11.3 ± 2.3%).
Figure 5. Effect of Sul-121 treatment on ROS status. (A) Plasma H2O2 levels are increased in db/db vehicle 
and normalized in db/db Sul-121) (B) Urinary H2O2 excretion is increased similarly in both db/db vehicle 
and db/db Sul-121. (C) SOD1 expression is decreased in db/db vehicle and normalized in db/db Sul-121. (D) 
SOD2 expression is increased in db/db vehicle and further increased in db/db Sul-121. (E) SOD3 expression 
was not significantly different between groups. (F) COX2 expression was increased in db/db vehicle. (G) 
Glomerular protein carbonylation was increased in lean-Sul-121 and further increased in db/db vehicle. Protein 
carbonylation in db/db Sul-121 was similarly increased as in db/db vehicle. (H) Effect of Sul-121 on in-vitro 
ROS production. Stimulation of cultured mesangial cells with high glucose/insulin increased ROS production 
which could be inhibited by Sul-121 pretreatment. (I) Acute effects of Sul-121 on renal mitochondrial ROS 
production ex-vivo. Increased mitochondrial ROS production in db/db was decreased by Sul-121. *p < 0.05 db/
db vehicle vs lean vehicle, #p < 0.05 db/db Sul-121 vs db/db, **p < 0.05 as indicated by horizontal line, †p < 0.05 
glucose vs control, ‡P < 0.05 glucose + Sul-121 vs glucose.
www.nature.com/scientificreports/
8SCiENTifiC REPoRTS | 7: 11165  | DOI:10.1038/s41598-017-11582-6
To further investigate the individual endothelial components involved in vascular relaxation, dose response 
curves were constructed using specific inhibitors for eNOS (L-NMMA) and cyclo-oxygenase (indomethacin). 
The relative contribution of each component was calculated (Fig. 6B). In db/db Sul-121 mice, total relaxation was 
improved mainly by an increase in the NO and prostaglandin components (274 ± 55 and 429 ± 31 AUC for db/db 
vehicle and db/db Sul-121, respectively). In addition, the EDHF component was higher in db/db Sul-121 (76 ± 12 
AUC) compared to db/db vehicle (49 ± 6 AUC), although this did not reach statistical significance (p = 0.07).
Furthermore, we assessed the sensitivity of the smooth muscle cells to NO, using the NO donor sodium nitro-
prusside (SNP) (Fig. 6C). Relaxations of PE preconstricted aortic rings to SNP were significantly attenuated only 
in db/db vehicle (92.8 ± 1.9%) when compared to lean vehicle (98.1 ± 0.4%).
Correlations. To assess whether the improved ROS status or the normalization of endothelial function is 
contributing to the inhibition of renal damage progression in diabetic mice, we plotted correlations between albu-
minuria and plasma H2O2 levels (Fig. 7A) and between albuminuria and maximum endothelial mediated relax-
ation to ACh (Fig. 7B). Plasma H2O2 levels correlated positively with albuminuria (R2 = 0.38 p < 0.05) whereas 
maximal endothelial mediated relaxation correlated negatively with albuminuria (R2 = 0.33 p < 0.05) using data 
of the combined db/db vehicle and db/db Sul-121 groups.
Discussion and Conclusion
The present study is the first to document the beneficial action of long-term subcutaneous infusion of the novel 
compound, Sul-121, in a model of experimental T2DM. We demonstrate that Sul-121 provides two major bene-
fits. The first is the attenuated progression of albuminuria and the limited extent of diabetes related renal damage 
in the db/db model of T2DM. This was made evident by the slower advancement of albumin excretion rate, 
decreased focal glomerular sclerosis score, reduced glomerular ECM protein expression and normalization of 
glomerular size and kidney weight. Secondly, Sul-121 inhibited the development of endothelial dysfunction and 
normalized systemic ROS formation, which was supported by in-vitro experiments. Sul-121 treatment in lean 
mice had no major observable side-effects, indicating that it is a well-tolerated compound. Thus, Sul-121 inhibits 
the progression of experimental diabetic kidney damage via a mechanism that inhibits both oxidative stress and 
preserves endothelial function.
Figure 6. Sul-121 treatment restores endothelium mediated relaxation. (A) Relaxations to acetylcholine were 
reduced in aortic rings of db/db vehicle indicating endothelial dysfunction. Sul-121 restored relaxation to lean 
vehicle values. (B) Dissection of the components involved in relaxation demonstrated a significant increase 
of the combined NO + PG component in db/db Sul-121 vs db/db vehicle. *p < 0.05 db/db Sul-121 vs db/db 
vehicle. (C) Sensitivity of the aortic rings to the NO donor SNP demonstrated decreased NO sensitivity in db/db 
vehicle. *p < 0.05 db/db vehicle vs lean vehicle, #p < 0.05 db/db Sul-121 vs db/db vehicle.
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Importantly, treatment with Sul-121 did not affect metabolic and diabetic parameters. In both lean control 
and db/db mice, Sul-121 treatment had no effects on body weight, plasma glucose levels, water consumption or 
urine production, indicating that the protective effects of Sul-121 in diabetes were not mediated through a less 
severe diabetic state.
Rather, Sul-121 treatment had profound effects on the ROS status of the diabetic mice. First, Sul-121 normal-
ized plasma H2O2 levels to levels of lean controls. H2O2 is considered to be the stable end product of short-lived 
reactive oxygen radicals and plasma H2O2 levels are determined by the kinetics of H2O2 production and elimina-
tion16. As urinary H2O2 excretion did not differ between db/db vehicle and db/db Sul-121, this indicates that Sul-
121 indeed inhibits ROS production in diabetes. These findings were supported by our in-vitro experiments using 
the ROS probe H2DCFDA. There, Sul-121 was able to inhibit high glucose and insulin induced increase in ROS 
production in cultured mesangial cells, indicating that Sul-121 is able to decrease ROS production in response to 
high glucose. Further, we demonstrated that Sul-121 was able to inhibit increased ROS production by mitochon-
dria obtained from kidneys of diabetic db/db mice. These findings are in line with a previous study performed in 
adipose tissue-derived stem cells15, confirming the inhibitory effects of Sul compounds on mitochondrial ROS 
production. In addition to inhibiting ROS production, Sul-121 stimulated renal expression of superoxide dis-
mutases SOD1 and SOD2 through a yet unknown mechanism, which may have contributed to the decreased 
ROS status in db/db Sul-121. Finally, Sul-121 attenuated the up-regulation of renal COX2 expression in diabetic 
animals. COX2 expression is known to be induced by mitochondrial ROS production, and may contribute to 
disturbed autoregulation of glomerular blood flow in diabetes17. Taken together, these data demonstrate that Sul 
compounds can indeed reduce ROS production in diabetes confirming our hypothesis.
Further, Sul-121 had profound effects on endothelial mediated relaxation. In our study, vehicle treated db/db 
mice demonstrated substantial endothelial dysfunction, as evidenced by the impaired vasorelaxation to acetyl-
choline. Sul-121 treatment however, completely normalized endothelial function by restoring vasorelaxation of 
db/db mice to the level of lean control mice. Furthermore, Sul-121 treatment restored the NO sensitivity of the 
smooth muscle layer in diabetes. Endothelial dysfunction in the db/db models has been reported in numerous 
studies and is thought to be caused by reduced nitric oxide (NO) bioavailability as a consequence of oxidative 
stress. In keeping with this, the restored endothelial function in Sul-121 treated mice was associated with a nor-
malization of plasma H2O2 levels in db/db mice. Furthermore, dissection of the endothelial factors involved in 
relaxation, demonstrated an increased contribution of NO and prostaglandins in the Sul-121 treated db/db mice. 
These data therefore indicate that normalization of oxidative stress and availability of NO underlie the normali-
zation of endothelial function by Sul-121 in db/db mice.
Vascular endothelial dysfunction is often associated with renal endothelial dysfunction known to increase 
protein leakage over the filtration barrier, resulting in albuminuria5. Indeed, we found a significant correla-
tion between vascular endothelial function and albuminuria in the present study. Furthermore, in addition to 
restoring vascular endothelial function, Sul-121 treatment halted the progression of albuminuria in db/db mice. 
Moreover, kidney hypertrophy, glomerular size, focal glomerular sclerosis scores and glomerular fibronectin 
expression were significantly lower in Sul-121 treated db/db over vehicle treated db/db mice, indicating a reduc-
tion in glomerular damage. Taken together these data indicate that the improved ROS status by Sul-121 treatment 
prevented vascular- and glomerular endothelial function, thereby attenuating the development of diabetic kidney 
damage.
In addition to damage to the endothelium, albuminuria may also be aggravated by loss of podocytes18, 19 and 
changes in the distribution and expression of slit-diaphragm proteins20. In the db/db model, loss of glucose sensi-
tive podocytes is an early event and is already prominent at an age of 8 weeks, whereas the remaining majority of 
podocytes adapt to hyperglycemia and become resistant to diabetes-induced apoptosis18. Indeed, at the age of 10 
weeks (at the start of treatment), the db/db mice in the present study already had increased albuminuria over lean 
mice, possibly reflecting this early loss of susceptible podocytes. Albuminuria in db/db mice progressed further 
at the age of 16 weeks (week 6 of treatment) which was prevented by Sul-121 treatment. However at the end of 
the study, podocyte numbers were found similarly reduced in both vehicle and Sul-121 treated db/db mice, indi-
cating that the protective effects of Sul-121 treatment is not mediated through protection of the glucose resistant 
Figure 7. Albuminuria correlates with ROS status and endothelial function. (A) AER correlates significantly 
with plasma H2O2 concentrations (p < 0.05). (B) AER correlates significantly with maximal response to 
acetylcholine (p < 0.05).
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podocytes. Whether Sul-121 could protect the glucose sensitive podocytes at an earlier time point remains to be 
investigated in future studies.
Although the pharmacokinetics of Sul-121 are not fully known, the current study showed that Sul-121 plasma 
levels were significantly higher in db/db than in lean control mice. These differences cannot be simply explained 
by differences in body weight. As daily dosing was identical in lean control (low weight) and db/db mice (high 
weight), the opposite is expected, i.e. lower Sul-121 levels in db/db. Further, the administration of Sul-121 
through osmotic mini pumps exclude that differences in oral absorption may underlie the higher Sul-121 levels 
in db/db. Moreover, db/db mice had a much higher urinary output, which seems to exclude renal clearance as the 
elimination route of Sul-121. Taken together, these data point towards a decreased hepatic clearance of Sul-121 
in diabetes21 explaining its increased plasma concentration in db/db mice. Thus, it would be interesting in future 
studies to explore the pharmacodynamics/kinetics of Sul-121 to better understand its metabolism and clearance. 
Finally, we cannot exclude that the lower plasma levels of Sul-121 are contributing to the lack of major adverse 
effects in the lean mice.
Although the current study was carefully planned and executed, there are some limitations to consider. First, 
body weights in the db/db mice began to fall by week 4 of the experiment which corresponds with an age of four-
teen weeks. This is considerably earlier than the decline in body weight at the age 5 to 6 months reported before22. 
Moreover, plasma glucose levels at the start of the experiment (age 10 weeks) were already at 28 mM which is 
considerably higher that the 15 mM reported for this age23. In addition, renal interstitial damage and inflam-
mation were lower than expected from literature. At present, it is unclear why the db/db mice developed such a 
severe diabetic phenotype with mainly glomerular damage and low interstitial damage. Possibly, the relative high 
percentage of sugars in the institution’s standard RMH-B diet (4%) may be related to this. Regardless, this study 
demonstrates that Sul-121 treatment is effective even in a severely diabetic model.
Further, Sul-121 treatment caused a small (approximately 10%) but statistically significant increase in glo-
merular protein carbonylation in lean mice. This is surprising a no other adverse effects of Sul-121 was recorded 
in the present study. Furthermore, plasma H2O2 levels and expression of SOD1,2,3 and COX2 were all unaf-
fected in Sul-121 treated lean mice, providing no indications for increased oxidative stress in Sul-121 treated 
lean mice. In addition, our in-vitro experiments did not show an effect of Sul-121 on ROS production in control 
cells. Alternatively, Sul-121 might interfere with protein decarbonylation. However, the molecular pathways of 
protein decarbonylation are still incompletely understood and whether Sul-121 interferes with electron donation 
to Glutaredoxin-1 or other enzymes involved in protein decarbonlyation24 needs to be determined in future 
studies. Nevertheless, the small increase in glomerular carbonylation in the absence of ROS activation appears to 
be without functional consequences for the kidney. In conclusion, Sul-121 limits the progression of experimental 
diabetic kidney damage via a mechanism that preserves endothelial function and reduces oxidative stress. Sul-121 
may therefore represent a new therapeutic strategy to combat diseases characterized by endothelial dysfunction 
and oxidative stress, including diabetes, obesity and metabolic syndrome.
Methods
Animals. Experiments were approved by the Institutional Animal Care and Use Committee of the University 
of Groningen, Netherlands. Further, all methods were performed in accordance with the relevant guidelines and 
regulations. 16 male db/db (strain JAX000642) and 16 lean controls were purchased from Harlan, UK and were 
assigned into four groups: db/db vehicle (diabetic control), db/db Sul-121 (treated diabetic group), lean vehicle 
(non-diabetic control) and lean Sul-121 (to study effect of drug only). Osmotic mini pumps were implanted at 
the age of 10 weeks and replaced at 14 weeks. Mice were placed in metabolic cages for 24 hours every 2 weeks. 
Mice were housed conventionally with free access to standard pelleted food (RMH-B, Hope Farms, Woerden, 
Netherlands) and water. In the db/db vehicle group, one mouse became lethargic at week 1 and was prematurely 
terminated. In the db/db Sul-121 group, one mouse died during surgery at week 2 due to complications caused by 
the anaesthetic. Therefore, the number of animals in both db/db groups was reduced to n = 7.
An additional group of 5 db/db and 4 lean control mice were used for assessing renal mitochondrial ROS 
production.
Chemicals and compounds. Vascular studies were performed using fresh Krebs bicarbonate solution. Cell 
culture grade DMSO was obtained from Sigma-Aldrich (Zwijndrecht, Netherlands). Sul-121 (6-hydroxy-2,5,7,
8-tetramethylchroman-2-yl)(piperazin-1-yl)methanone) was supplied by Sulfateq bv, Groningen, Netherlands.
Mini-pumps and dose of Sul-121. Previous unpublished experiments demonstrated that bolus infusions 
up to 30 mg/kg Sul-121 could be administered safely to mice. Therefore the maximal attainable dose of Sul-121 
was chosen in the current study. For this, Alzet 2004 pumps were loaded with 200 µl of 12.6 g/l Sul-121 in 50% 
DMSO (or with 200 µl 50% DMSO solution as vehicle), resulting in a daily dose Sul-121 of 2.2 mg/kg/day for a 
35gram mouse (range 1.8–2.82 mg/kg/day for the heaviest and lightest mouse in the study). Pumps were surgi-
cally implanted into a subcutaneous pocket in the dorsal midscapular area of the mouse.
Sul-121 measurement. Blood samples for Sul-121 analysis were obtained two weeks after implantation of 
the first osmotic minipump. Sul-121 analysis was performed on an Agilent 6460 A (Santa Clara, Ca, USA) triple 
quadrupole LC-MS/MS system, with a combined Agilent 1200 series LC system. A HyPURITY® C18 analytical 
column from ThermoFisher Scientific (Waltham, MA, USA) was used for chromatographic separation by means 
of a gradient with a flow of 0.5 mL/min and a run time of 2.4 min. Sample preparation was performed by means 
of protein precipitation.
Urinary measurements. Urinary glucose was measured by the glucose oxidase method with a specific elec-
trode. Creatinine was measured by Jaffe method without deproteinization, DiaSys Diagnostic Systems, Holzheim, 
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Germany. Albumin was determined manually using a mouse albumin Elisa kit, Abcam (ab108792), Cambridge, 
UK).
Blood pressure measurement. Arterial blood pressure was measured in anaesthetized mice (2% isoflu-
rane) by means of the tail-cuff method (PS-200A; Riken-Kaihatsu; Tokyo, Japan). For each animal, blood pressure 
values represented the mean of three to ten recordings.
Myography. Thoracic aorta was surgically removed and stored in cold saline (4 °C). Aortas were cleaned from 
fat or connective tissue and cut into rings of 1.7–2.5 mm width. Rings were mounted in myograph baths (Danish 
Myo Technology, Aarhus, Denmark). Contractions were measured as cumulative concentration-response curves 
to phenylephrine followed by a single concentration of KCl (90 mM). Endothelium-dependent relaxation was 
assessed by obtaining concentration-response curves to ACh in rings precontracted with PE (1 μM) followed by 
stimulation with a high concentration of the NO donor sodium nitroprusside (SNP; 0.1 mM) to assess maximal 
endothelium-independent dilation. To examine the contribution of different EDRFs, inhibitors of PG (10 μM 
indomethacin) and NO synthesis (L-NMMA; 1 μM) were used. The remaining ACh-mediated relaxation was 
attributed to an unidentified EDHF.
Histology and morphological analysis. For PAS and Sirius Red staining, Kidneys fixed in paraformalde-
hyde were cut into 4 μM sections, deparaffinised and stained with periodic acid-Schiff (PAS) or Sirius Red. Sirius 
Red staining was performed by incubating slides in 0.1% Sirius Red (manufacturer) for 60 minutes, washing twice 
with 1% acetic acid. Both PAS and Sirius Red Staining were subsequently dehydrated with 100% ethanol and 
cleared with xylene. Kidney sections stained with PAS were viewed under bright field illumination at 20x (Nikon 
Eclipse 50I). Glomerulosclerosis was scored in a blinded fashion by measuring mesangial expansion. For this, the 
circumference of the affected area in each glomerulus was drawn manually and the surface of this area was sub-
sequently determined in Fiji version 2.00 (National Institutes of Health, USA). 10–50 glomeruli per kidney were 
analyzed. Kidney sections stained with Sirius Red were viewed under dark field illumination at 20x (TissueFAXs 
TissueGnostics). Whole scans were made and were analysed automatically according to method described by 
Street et al.25. For immunohistochemistry, kidney cryosections were cut into 4 micrometer sections, and stained 
for Nephrin (1:100, AF3159-SP, R&D research), WT1 (1:150, sc-192, Santa Cruz), Synaptopodin (1:100, sc-21537, 
Santa Cruz), anti-VWF (1:100, A008202, Dako), Fibronectin (1:100, sc-6952, Santa Cruz), dapi (nuclei) and 
Phalloidin (actin) (Texas Red-X, Thermofisher Scientific).
For the quantification of glomerular size and podocyte numbers, whole slide imaging was performed. 
Glomerular size was measured with ImageJ (NIH, v1.5i) only when the vascular pole was clearly visible. A min-
imum of 30 glomeruli per mouse was measured. The number of podocytes were quantified by the colocalization 
of DAPI and WT-1. A minimum of 32 glomeruli per mouse was counted.
For the localization of carbonylated proteins in kidney samples, the tissue had been fixed and was subse-
quently incubated with DNPH-solution diluted 1:100 in PBS. Afterwards unspecific antibody binding sides were 
blocked and the tissue stained with an anti-DNP-antibody (invitrogen, A11097, 1:100 dilution).
Real-Time PCR. RNA from kidneys was isolated using a RNA isolation kit (NucleoSpin® RNA II, 
Macherey-Nagel GmbH & Co. KG). The integrity of RNA was determined using agarose gel electrophore-
sis, and the RNA concentration was measured spectrophotometrically at 260 nm. RNA (1 μg) was reversely 
transcribed into cDNA. Real-Time PCR was performed using AbsoluteTM QPCR SYBR® Green ROX Mix 
(Westburg, Leusden, Netherlands), 400 nM of primer and 2,5 μl template DNA in a total volume of 25 μl. 
Quantitative real-time PCR was performed at 95 °C for 15 minutes followed by 40 cycles of denaturing at 95 °C 
for 15 seconds and annealing/ extending at 60 °C for 1 minute. Real-Time PCR for beta actin (forward primer: 
5′-CGCCACCAGTTCGCCATGGA-3′, reverse primer: 5′-TACAGCCCGGGGAGCATCGT-3′), SOD1 (for-
ward primer: 5′-AAGGCCGTGTGCGTGCTGAA-3′, reverse primer: 5′-ATCCGCTGGACCGCCATGTT-3′), 
S O D 2  ( f o r w a r d  p r i m e r :  5 ′ - G G C G A C C TA C G T G A A C A AT C T- 3 ′ ,  r e v e r s e  p r i m e r : 
5′-TTGATAGCCTCCAGCAACTC-3′), SOD3 (forward primer: 5′-GACCGGCTTGACCTGGTTGA-3′, 
r e v e r s e  p r i m e r :  5 ′ - C C A C G A A G T T G A C G A A G T C C - 3 ′ ) ,  C O X 2  ( f o r w a r d  p r i m e r : 
5′-CTGTATCCCGCCCTGCTGG-3′, reverse primer: 5′-AAGACAGCCACCATCAACG-3′), CD68 (forward 
primer: 5′-AAGCAGCACAGTGGACATTC-3′, reverse primer: 5′-ATGATGAGAGGCAGCAAGAG-3′), Il-1B 
(forward primer: 5′-CTGTGGCAGCTACCTATGTC-3′, reverse primer: 5′-CACACTAGCAGGTCGTCATC-3′), 
T N F- a  ( for w ard  pr i m e r :  5 ′ - AC A A AG G TG C C G C TA AC C AC ATG T- 3 ′ ,  re ve r s e  pr i m e r : 
5′-ATGCTGCTGTTTCAGTCGAAGGCA-3′), SMA (forward primer: 5′-CCATCATGCGTCTGGACTTG-3′, 
reverse primer: 5′-AATCTCACGCTCGGCAGTA-3′) and Collagen-1 (forward primer: 5′-GGCCATTGGT 
GGTGCTGAC-3′, reverse primer: 5′-TAAAGGAGGAAACGGCAAAG-3′) was performed using AbsoluteTM 
QPCR SYBR® Green ROX Mix (Westburg, Leusden, Netherlands), 400 nM of each primer and 2 μl template 
DNA in a total volume of 10 μl. Quantitative real-time PCR was performed at 95 °C for 15 minutes followed by 40 
cycles of denaturing at 95 °C for 15 seconds and annealing/extending at 60 °C for 30 seconds, 75 °C for 30 seconds. 
PCR product specificity and purity were evaluated by generating a dissociation curve following the manufactur-
er’s recommendations.
Western blotting. Frozen kidneys tissues were homogenized in cold RIPA with protease inhibitors and pro-
tein concentrations were determined by the Bio Rad DC protein assay. Proteins were separated by gel electropho-
resis and transferred onto nitrocellulose membrane. Antibodies used for detection: beta-actin (sc-47778, Santa 
Cruz), Nephrin (AF3159-SP, R&D research), Fibronectin (sc-6952, Santa Cruz, Heidelberg, Germany), Protein 
expression was detected by a GeneGnome and images were analysed with Fiji.
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Plasma measurements. Plasma creatinine levels were determined using a Cayman Creatinine (serum) 
Colorimetric Assay Kit (Cayman, Ann Arbor, USA). Plasma hydrogen peroxide levels were determined using an 
Amplex Red H2O2 kit, Life technologies (A22188), Leusden, Netherlands.
Cell culture and ROS production. Mouse mesangial cells (MMC) were cultured in DMEM containing 
penicillin and streptomycin supplemented with 10% fetal calf serum. ROS production was measured in 96 wells 
plates using the probe H2DCF-DA (C2938; Molecular probes). MMCs were first incubated in DMEM containing 
1 g/l glucose 24 hours. Near confluent mesangial cells were loaded with dye for 1 hour at 37 °C. Afterwards, cells 
were washed and incubated with or without Sul-121 (100 nM) for 30 minutes. ROS production was stimulated 
by incubation in high glucose (4.5 g/l) and insulin (0.1 unit/ml) for 1 hour. Fluorescence was measured using a 
Synergy H4 microplate reader.
Renal mitochondrial ROS production was measured in an additional cohort of lean (n = 4) and db/db 
(n = 5) mice. For this, the kidney was excised and immediately stored in cold saline for no more than 2 hours. 
Subsequently, the kidney was cut into smaller pieces and a 100 mg kidney fragment was transferred into an 
eppendorf vial containing 0.5 ml of cold extraction buffer (10 mM HEPES pH 7.5, 200 mM mannitol, 70 mM 
sucrose and 1 mM EGTA). The tissue was homogenized and subsequently centrifuged at 600*g for 5 minutes. 
The supernatant was transferred to a new tube and centrifuged at 11.000 g for 10 minutes. The pellet was resus-
pended in 0.5 ml extraction buffer and the two centrifugation steps described above, were repeated. The resulting 
pellet was resuspended in storage buffer (10 mM HEPES pH 7.5, 250 mM sucrose, 1 mM ATP, 80 µM ADP, 5 mM 
sodium succinate, 2 mM K2HPO4 and 1 mM DTT). Protein concentrations were determined by a DC protein 
assay (Biorad). For measuring mitochondrial ROS production, 2 µg of mitochondria was transferred into 50 µl 
assay buffer (20 mM MOPS pH7.5, 110 mM KCl, 10 mM ATP, 10 mM KCl, 10 mM sodium pyruvate and 1 mM 
EGTA) supplemented with 100 µM Amplex Red en 0.2U/ml HRP (Invitrogen). To evaluate the acute effects of 
SUL-121 on mitochondrial ROS production, 1 µM of Sul-121 was added to the reaction mixture. The Amplex Red 
reaction was performed at 37 °C for two hours. Fluorescent detection was performed at 540/590 nm in a Biotek 
Synergy 4 plate reader.
Data analysis and calculations. Data are presented as means ± SE, and n refers to the number of animals 
in each group. Statistical analysis was done with SPSS version 22 for Windows (SPSS, Chicago, IL). Differences 
between full concentration-response curves were tested with repetitive measures ANOVA; differences between 
points were tested with one-way ANOVA. P values of <0.05 (two tailed) were considered statistically significant.
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